Page 1, delete the second paragraph between lines 7-12 in its entirety, and substitute the following paragraph:

B2 This application is related to and claims priority to the United States Provisional Application Serial Number 60/089,521 which was filed by Tang, *et al.* on June 16, 1998 and entitled "METHODS FOR TREATING DISEASES AND DISORDERS RELATED TO UNREGULATED ANGIOGENESIS AND/OR VASCULOGENESIS" which is hereby incorporated by reference herein in its entirety including any drawings.

Page 8, paragraph 1, delete in its entirety, and substitute the following paragraph:

B3 Formulations for indolinone compounds are described in U.S. Application Serial No. 08/702,232, filed August 23, 1996 and in the corresponding International patent publication WO 96/22976. Specific examples of parenteral and oral formulations for lipophilic compounds are contained in U.S. Patent 5,610,173, issued March 11, 1997, entitled "Formulations for Lipophilic Compounds" by D. Schwartz, *et al.* and U.S. Patent Application Serial No. 09/034,374, filed March 4, 1998, entitled "Formulations for Hydrophobic Pharmaceutical Composition" by N. Shenoy, *et al.* and PCT Application No. PCT/US98/04134, filed March 4, 1998, entitled "Formulations for Hydrophobic Pharmaceutical Compositions" by N. Shenoy, *et al.,* which are hereby included herein by reference in their entirety, including any drawings, figures, and tables.

Page 51, paragraph 4, delete in its entirety, and substitute the following paragraph:

B4 Indolinone compounds of the invention can be tested for their ability to activate or inhibit protein kinases in biological assays. The methods used to measure indolinone modulation of protein kinase function are described in U.S. Application Serial No. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.*, incorporated herein by reference in its entirety, including any drawings. Indolinone compounds of the invention were tested for their ability to inhibit the FLK protein kinase. Further activities and methods are described in US Patent Application Serial No. 60/045,566, filed May 5, 1997, entitled "FLK Specific Indolinone Compounds and

Related Products and Methods for the Treatment of Disease" by McMahon *et al.*, and U.S. patent application Serial No. 08/915,366, filed August 20, 1997, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.*, both of which are hereby included herein by reference in their entirety including any figures and drawings.

B4 Cont'd

Page 56, first paragraph, after the title, delete in its entirety, and substitute the following paragraph:

The methods of the invention include the administration of indolinone compounds to patients in formulations. Formulations for indolinone compounds are described in U.S. Application Serial No. 08/702,232, filed August 23, 1996 and in International patent publication No. WO 96/22976. Some indolinone compounds are insoluble in aqueous environments, so they require the addition of compounds that can be solubilize them before administration of the pharmaceutical agents to a patient. Specific formulations, methods of making and methods of use for hydrophobic indolinone compounds are described in U.S. Patent Serial No. 5,610,173 entitled "Formulations for Lipophilic Compounds" by D. Schwartz *et al.,* U.S. Patent Application Serial No. 09/034,374, entitled "Formulations for Hydrophobic Pharmaceutical Agents," filed March 4, 1998, and the PCT application PCT/US98/04134, of the same title, also filed March 4, 1998, all hereby incorporated by reference herein in their entirety including any drawings, figures, or tables. The components of the formulations bind to the hydrophobic regions of the pharmaceutical agents exposing the polar regions of the solubilizing components to the solvent environment. This encapsulation of the pharmaceutical agents renders them soluble in aqueous environments.

B5

Page 22, paragraph 2, delete in its entirety, and substitute the following paragraph:

Another aspect of the invention features methods of identifying one or more indolinone compounds that inhibit growth factor-stimulated cell proliferation comprising the following steps: (a) contacting cells with one or more indolinone compounds of Formula I; (b) contacting the cells with one or more growth factors selected from the group consisting of VEGF, PDGF, and FGF; and (c) monitoring an effect upon the cells.

B6